A synthetic peptide fragment of vitronectin
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

VnP-16 (trifluoroacetate salt)

Item No. 38839

Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(6S,9S,12S,15S,18S,21S,27S,30S,33S,36S,39S)-36-((1H-indol-3-yl)methyl)-1,6-diamino-30-(3-amino-3-oxopropyl)-21,27-bis(4-aminobutyl)-15,18-dibenzyl-39-carbamoyl-12,33-bis(4-hydroxybenzyl)-1-imino-9-isopropyl-7,10,13,16,19,22,25,28,31,34,37-undecaoxo-2,8,11,14,17,20,23,26,29,32,35,38-dodecaazadotetracontan-42-oic acid, trifluoroacetate salt
Molecular Formula
C82H112N20O17 • XCF3COOH
Formula Weight
1649.9
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: 2 mg/mlPBS (pH 7.2): 5 mg/ml
SMILES
[H]N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(N)=O)=O)CC1=CNC2=C1C=CC=C2)=O)CC3=CC=C(O)C=C3)=O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)CC5=CC=CC=C5)=O)CC6=CC=C(O)C=C6)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C82H112N20O17.C2HF3O2/c1-47(2)70(102-72(110)56(85)21-15-39-90-82(88)89)81(119)101-65(43-51-27-31-54(104)32-28-51)79(117)99-63(41-49-18-7-4-8-19-49)77(115)98-62(40-48-16-5-3-6-17-48)76(114)95-59(23-11-13-37-83)73(111)92-46-68(106)93-60(24-12-14-38-84)74(112)96-61(33-35-67(86)105)75(113)97-64(42-50-25-29-53(103)30-26-50)78(116)100-66(44-52-45-91-57-22-10-9-20-55(52)57)80(118)94-58(71(87)109)34-36-69(107)108;3-2(4,5)1(6)7/h3-10,16-20,22,25-32,45,47,56,58-66,70,91,103-104H,11-15,21,23-24,33-44,46,83-85H2,1-2H3,(H2,86,105)(H2,87,109)(H,92,111)(H,93,106)(H,94,118)(H,95,114)(H,96,112)(H,97,113)(H,98,115)(H,99,117)(H,100,116)(H,101,119)(H,102,110)(H,107,108)(H4,88,89,90);(H,6,7)/t56-,58-,59-,60-,61-,62-,63-,64-,65-,66-,70-;/m0./s1
InChi Key
XOESAVBSGACZHG-BGZBGOTLSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $28

    Add

    5 mg

    $104

    Add

    10 mg

    $193

    Add

    25 mg

    $413

    Add
    Product Description

    VnP-16 is a synthetic peptide fragment that corresponds to amino acids 270-281 of vitronectin, a multifunctional glycoprotein with roles in cell attachment, migration, and spreading.1 It induces attachment and cell spreading of isolated human osteogenic cells, an effect that can be reversed by siRNA knockdown of β1 integrin, when applied to cell plates at a concentration of 9.1 µg/cm2. VnP-16 induces osteogenesis of human skin-derived mesenchymal precursors and MC3T3-E1 mouse calvarial osteoblast precursors. In vivo, VnP-16 decreases IL-1α-induced bone loss and decreases the number of calvarial osteoclasts in mice. It also increases bone mineral density and decreases trabecular bone loss in a mouse model of ovariectomy-induced bone loss.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Min, S.-K., Kang, H.K., Jung, S.Y., et al. A vitronectin-derived peptide reverses ovariectomy-induced bone loss via regulation of osteoblast and osteoclast differentiation. Cell Death Differ. 25(2), 268-281 (2017).